Investigation of Anticoagulation Strategies in Nonvalvular Atrial Fibrillation Patients Aged 80 and Over
Cardiovascular Department,the Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310005,China
*Corresponding author:HUANG Shuwei,Chief physician;E-mail:cc123X@163.com
[1]KIRCHHOF P,BENUSSI S,KOTECHA D,et al.2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Rev Esp Cardiol(Engl Ed),2017,70(1):50.DOI:10.1016/j.rec.2016.11.033.
[2]ZHOU Z Q,HU D Y.An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China[J].J Epidemiol,2008,18(5):209-216.DOI:10.2188/jea.je2008021.
[3]黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗的建议—2018[J].中国心脏起搏与心电生理杂志,2018,32(4):315-368.DOI:10.13333/j.cnki.cjcpe.2018.04.001.http://kns.cnki.net/kcms /detail/42.1421.R.20180815.1517.001.html.
[4]CHAN Y H,YEN K C,SEE L C,et al.Cardiovascular,bleeding,and mortality risks of dabigatran in asians with nonvalvular atrial fibrillation[J].Stroke,2016,47(2):441-449.DOI:10.1161/STROKEAHA.115.011476.
[5]CONNOLLY S J,EZEKOWITZ M D,YUSUF S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.DOI:10.1056/NEJMoa0905561.
[6]PATEL M R,MAHAFFEY K W,GARG J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.DOI:10.1056/NEJMoa1009638.
[7]BITEKER M,BASARAN O,DOGAN V,et al.Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation:results from the ReAl-life multicenter survey evaluating stroke study[J].J Am Geriatr Soc,2017,65(8):1684-1690.DOI:10.1111/jgs.14855.
[8]SEREBRUANY V L,ATAR D.Assessment of bleeding events in clinical trials—proposal of a new classification[J].Am J Cardiol,2007,99(2):288-290.DOI:10.1016/j.amjcard.2006.07.091.
[9]SENOO K,AN Y,OGAWA H,et al.Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom[J].Heart,2016,102(23):1878-1882.DOI:10.1136/heartjnl-2016-309741.
[10]CHIANG C E,OKUMURA K,ZHANG S,et al.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J].J Arrhythm,2017,33(4):345-367.DOI:10.1016/j.joa.2017.05.004.
[11]GUO Y T,APOSTOLAKIS S,BLANN A D,et al.Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation[J].Int J Cardiol,2013,168(2):904-909.DOI:10.1016/j.ijcard.2012.10.052.
[12]CORVOL A,GULSVIK A K,KUPER I M J A,et al.Use of anticoagulants for atrial fibrillation in older subjects across different countries:Cyprus,France,Netherlands,Norway[J].Eur Geriatr Med,2014,5(1):60-65.DOI:10.1016/j.eurger.2013.10.013.2013.10.013.
[13]李晶,石婧,林琴,等.年龄≥80岁高龄非瓣膜病心房颤动患者抗栓治疗与脑卒中的相关性[J].中华高血压杂志,2018,26(8):800.DOI:10.16439/j.cnki.1673-7245.2018.08.035.http://www.cnki.com.cn/Article/CJFDTotal-ZGGZ201808037.htm.
[14]MANT J,HOBBS F D,FLETCHER K,et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial[J].Lancet,2007,370(9586):493-503.
[15]YAMAJI H,HIGASHIYA S,MURAKAMI T,et al.Effects of oral anticoagulants on patients with atrial fibrillation aged 90 years and older[J].J Cardiovasc Pharmacol,2019,74(3):246-254.DOI:10.1097/fjc.0000000000000703.
[16]DEITELZWEIG S,KESHISHIAN A,LI X Y,et al.Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients[J].J Am Geriatr Soc,2019,67(8):1662-1671.DOI:10.1111/jgs.15956.